GGrantIndex
Sort

64,565 grants matching drug discovery

MIGRAINE--PATHOPHYSIOLOGY AND TREATMENT MECHANISMS

$1,144,788
Massachusetts General Hospital · P01 · FY2000 · NS

Discovering accumulation guidelines and applying them to develop new antibiotics for Gram-negative pathogens

$1,144,714
Paul Hergenrother · University Of Illinois At Urbana-Champaign · R01 · FY2025 · AI

Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD

$1,144,570
Nilufer Ertekin-Taner · Mayo Clinic Jacksonville · R01 · FY2018 · AG

A functional evolutionary genetic approach to combat viral infection

$1,144,500
John W. Schoggins · Ut Southwestern Medical Center · DP1 · FY2020 · AI

Personalized Cystic Fibrosis Therapy and Research Center

$1,144,093
Anjaparavanda P Naren · Cincinnati Childrens Hosp Med Ctr · P30 · FY2021 · DK

Molecular Pathogenesis of Neoplasia

$1,143,869
Russell Lonser · National Institute Of Neurological Disorders And Stroke · ZIA · FY2009 · NS

Molecular Correlates Of Human Ca2+ Channel Regulation

$1,143,539
Nikolai Soldatov · National Institute On Aging · Z01 · FY2008 · AG

Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic Islets

$1,143,103
D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · UG3 · FY2019 · DK

Center for Genomics and Society

$1,142,549
Gail E Henderson · Univ Of North Carolina Chapel Hill · P50 · FY2011 · HG

First-in-Class Macrocyclic Peptide Therapeutic For Rheumatoid Arthritis

$1,142,534
Dat Quang Tran · Oryn Therapeutics, Llc · R44 · FY2015 · AR

Open Drug Discovery Center for Alzheimer's Disease

$1,142,384
Allan I Levey · Emory University · U54 · FY2023 · AG

TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)

$1,142,366
Payam Nahid · University Of California, San Francisco · R01 · FY2017 · AI

Identification of novel MDR antimicrobials from insect-Streptomyces symbioses

$1,142,106
Cameron Robert Currie · University Of Wisconsin-Madison · U19 · FY2020 · AI

Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses

$1,142,044
Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2017 · AI

Metal-Catalyzed Methods for Organic Synthesis

$1,141,967
Stephen L Buchwald · Massachusetts Institute Of Technology · R35 · FY2022 · GM

Metal-Catalyzed Methods for Organic Synthesis

$1,141,967
Stephen L Buchwald · Massachusetts Institute Of Technology · R35 · FY2025 · GM

Metal-Catalyzed Methods for Organic Synthesis

$1,141,967
Stephen L Buchwald · Massachusetts Institute Of Technology · R35 · FY2023 · GM

Metal-Catalyzed Methods for Organic Synthesis

$1,141,967
Stephen L Buchwald · Massachusetts Institute Of Technology · R35 · FY2024 · GM

Effect of Tumors on the Skeleton

$1,141,868
Florent Elefteriou · Vanderbilt University · P01 · FY2009 · CA

Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors

$1,141,669
D. Martin Watterson · Northwestern University At Chicago · U01 · FY2014 · AG

DCTD Human Toxicology and Pharmacology

$1,141,659
David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2015 · CA

Role of a psychiatric disease risk factor in synaptic function and gene transcription regulation

$1,141,539
Hongjun Song · University Of Pennsylvania · U19 · FY2020 · MH

Discovering antimicrobials acting against MDR pathogens

$1,141,522
Kim Lewis · Northeastern University · R01 · FY2023 · AI

Small-molecule inhibitors of flavivirus entry

$1,141,241
Priscilla Li-Ning Yang · Harvard Medical School · U19 · FY2014 · AI

Novel Small-Molecule Therapies for CF

$1,140,903
Alan S Verkman · University Of California, San Francisco · P30 · FY2011 · DK